Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 11—November 2018
Dispatch

Hospitalizations for Influenza-Associated Severe Acute Respiratory Infection, Beijing, China, 2014–2016

Yi Zhang, David J. Muscatello, Quanyi WangComments to Author , Peng Yang, Yang Pan, Da Huo, Zhongcheng Liu, Xiaojuan Zhao, Yaqing Tang, Chao Li, Abrar A. Chughtai, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (Y. Zhang, D.J. Muscatello, A.A. Chughtai, C.R. MacIntyre); Beijing Municipal Centre for Disease Prevention and Control, Dongcheng District, Beijing, China (Y. Zhang, Q. Wang, P. Yang, Y. Pan, D. Huo); Beijing Research Center for Preventive Medicine, Beijing (Y. Zhang, Q. Wang, P. Yang, Y. Pan, D. Huo); Chang Ping Centre for Disease Prevention and Control, Changping District, Beijing (Z. Liu, Y. Tang); Huai Rou Centre for Disease Prevention and Control, Huairou District, Beijing (X. Zhao, C. Li); Arizona State University, Phoenix, Arizona, USA (C.R. MacIntyre)

Main Article

Table 2

Outcomes of SARI patients with and without laboratory-confirmed influenza. Beijing, China, week 40, 2014–week 39, 2016*

Characteristic All SARI patients, n = 2,212 SARI patients without confirmed influenza, n = 1,759 SARI patients with confirmed influenza, n = 453 p value†
Sex
M 1,298 (58.7) 1,030 (58.6) 268 (59.2) 0.816
F
 914 (41.3)
 729 (41.4)
 185 (40.8)
Age group, y
0–4 973 (44.0) 778 (44.2) 195 (43.1) <0.001
5–14 368 (16.6) 260 (14.8) 108 (23.8)
15–24 40 (1.8) 35 (2.0) 5 (1.1)
25–59 284 (12.8) 235 (13.4) 49 (10.8)
>60
 547 (24.7)
 451 (25.6)
 96 (21.2)
Underlying medical condition
>1‡ 548 (24.8) 450 (25.6) 98 (21.6) 0.083
Pulmonary diseases§ 224 (10.1) 175 (10.0) 49 (10.8) 0.585
Cardiovascular diseases 380 (17.2) 321 (18.3) 59 (13.0) 0.009
Metabolic diseases¶ 71 (3.2) 61 (3.5) 10 (2.2) 0.175
Renal dysfunction 22 (1.0) 19 (1.1) 3 (0.7) 0.424
Hepatic dysfunction 10 (0.5) 10 (0.6) 0 (0.0) 0.108
Tumor 31 (1.4) 27 (1.5) 4 (0.9) 0.292
Immune system diseases
 1 (0.1)
 1 (0.1)
 0 (0.0)
 0.612
Received influenza vaccine within 1 y
 121 (5.5)
 90 (5.1)
 31 (6.8)
 0.15
Treatment
Antiviral drugs 30 (1.4) 14 (0.8) 16 (3.5) <0.001
Antibacterial drugs 2,171 (98.2) 1,722 (97.9) 449 (99.1) 0.086
Corticosteroids 214 (9.7) 154 (8.8) 60 (13.3) 0.004
Oxygen therapy 589 (26.6) 492 (28.0) 97 (21.4) 0.005
Mechanical ventilation
 12 (0.5)
 8 (0.5)
 4 (0.9)
 0.428
Complication 510 (23.1) 415 (23.6) 95 (21.0) 0.237
Pneumonia
 389 (17.6)
 321 (18.3)
 68 (15.0)
 0.106
Median length of hospital stay, d (IQR)
 8.8 (8.6–9.0)
 9.0 (8.7–9.3)
 8.0 (7.5–8.4)
 <0.001
Admission to ICU
 28 (1.3)
 20 (1.1)
 8 (1.8)
 0.286
Died 9 (0.4) 8 (0.5) 1 (0.2) 0.485

*Values are no. (%) unless otherwise indicated. The weeks range from 2014 Sep 29 through 2016 Oct 2. ICU, intensive care unit; IQR, interquartile range; SARI, severe acute respiratory infection.
†Calculated by χ2 test.
‡Defined as any inpatient stays with admission diagnosis in any of the following diseases, symptoms, or signs: pulmonary disease, cardiovascular disease, chronic metabolic disease, renal dysfunction, hepatic diseases, or tumor.
§Asthma, chronic obstructive pulmonary disease, emphysema, chronic bronchitis.
¶Diabetes, dyslipidemia.

Main Article

Page created: October 16, 2018
Page updated: October 16, 2018
Page reviewed: October 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external